Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast Ophthalmic Solution for Dry Eye (Phase III, China)
CTR20221357Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lifitegrast in dry eye syndrome (DED), sponsored by Qilu Pharmaceutical. Started Jun 2022; status: completed.
02
Drugs
lifitegrast
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20221357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221357.